BPMC — Blueprint Medicines Income Statement
0.000.00%
Last trade - 00:00
- $5.32bn
- $4.85bn
- $249.38m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 66.5 | 794 | 180 | 204 | 249 |
Cost of Revenue | |||||
Gross Profit | — | 793 | 162 | 186 | 241 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 428 | 485 | 822 | 742 | 736 |
Operating Profit | -361 | 309 | -642 | -538 | -486 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -348 | 315 | -641 | -552 | -506 |
Provision for Income Taxes | |||||
Net Income After Taxes | -348 | 314 | -644 | -558 | -507 |
Net Income Before Extraordinary Items | |||||
Net Income | -348 | 314 | -644 | -558 | -507 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -348 | 314 | -644 | -558 | -507 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -7.27 | 5.59 | -11 | -9.35 | -8.37 |